Veeva Systems Inc (VEEV)
Health Care · Health Care Technology · US stock · S&P 500 component
$310.36
▼ -2.67 (0.85%)
Fair valueFair
$240 −22.8% to fair value
$120fair band $168–$311$359
Day's range
$306.58 – $319.95
52-week range
$148.05 – $319.95
About Veeva Systems Inc
Veeva Systems provides cloud software and data services built specifically for the life sciences industry, serving pharmaceutical, biotechnology and medical device companies. Its products help customers manage clinical trials, regulatory submissions, quality processes, and the commercial side of selling medicines to doctors. Revenue is largely recurring, coming from subscriptions to its software applications and from related data and professional services. Customers are typically regulated businesses that rely on these systems for core operations.
The figures show revenue of $3.5 billion for the last twelve months and three-year growth of 14.0% a year. It reports an operating margin of 29.9%. Capital is used to generate a return on invested capital of 233%. It does not currently pay a dividend. The site's X-Ray Score for the company is 65 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $148.05 – $319.95Volume 1,730,100Daily, split-adjusted
Vitals
Market cap$51.2B
52-week range$148.05 – $319.95
Volume (last day)1,730,100
P/E (TTM)51.0
EBIT / EV yield2.3%
Free-cash-flow yield–
Dividend yieldNo dividend
Revenue (TTM)$3.5B
Net income (TTM)$1.0B
Operating margin29.9%
Return on capital232.6%
Debt incl. leasesData missing
Cash & securities$7.2B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$240model spread $214 – $262
Fair
−22.8% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $310
Undervalued < $168Fair $168 – $311Overvalued > $311
10-year DCF (market-scaled)
$353
Peer multiples
$181
Earnings power floor (not blended)
$84
Fundamentals-adjusted multiple
$185
Growth the price implies
30.1%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Strong business at a fair price
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
34/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield2.3%
Fair value vs price0.8×
Growth
Strong
82/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)14.0%
EPS growth (3y)21.9%
Growth consistency100%
Profitability
Strong
72/100
Earns high returns on the capital it uses.
See the numbers →
Return on invested capital232.6%
Operating margin29.9%
Gross profitability28.6%
Financial health
Strong
81/100
Balance sheet looks strong: debt is well covered.
See the numbers →
Piotroski F-Score7 / 9
Interest coverNo interest cost
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+16.7%
Apr '25
+16.7%
Jul '25
+16.0%
Oct '25
+16.0%
Jan '26
+16.3%
Apr '26
+17.6%
Jul '26
Revenue against the same quarter a year earlier. Latest quarter revenue $928M, diluted EPS $1.66.
Fundamentals checklist
● 9 Good · ● 3 Average · ● 1 BadCash quality
Earnings backed by cashGood
Risk models
Altman Z''Good
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioGood
Interest coverGood
Valuation
Fair value vs priceAverage
EBIT / EV yieldBad
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 72/100.
Financials
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Revenue | $1.9B | $2.2B | $2.4B | $2.7B | $3.2B |
| Operating income | $505M | $459M | $429M | $691M | $916M |
| Net income | $427M | $488M | $526M | $714M | $909M |
| Operating cash flow | $764M | $780M | $911M | $1.1B | $1.4B |
| Operating margin | 27.3% | 21.3% | 18.2% | 25.2% | 28.7% |
| Free cash flow | – | – | – | – | – |
| Diluted EPS | $2.63 | $3.00 | $3.22 | $4.32 | $5.44 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 2 neutral · 2 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 294.9 | Bullish |
| EMA 10 | 297.1 | Bullish |
| SMA 20 | 284.8 | Bullish |
| EMA 20 | 287.8 | Bullish |
| SMA 50 | 268.8 | Bullish |
| EMA 50 | 265.9 | Bullish |
| SMA 100 | 225.5 | Bullish |
| EMA 100 | 241.4 | Bullish |
| SMA 200 | 204.9 | Bullish |
| EMA 200 | 227.2 | Bullish |
Oscillators (daily)
| RSI (14) | 71.19 | Bearish |
| MACD (12, 26) | 11.73 | Bullish |
| Momentum (12) | 8.73 | Bullish |
| Stochastic %K (14) | 79.64 | Neutral |
| Williams %R (14) | -20.36 | Neutral |
| CCI (20) | 176.6 | Bearish |
Pivot points (classic, last session)
S3 291.3 | S2 298.9 | S1 304.6 | Pivot 312.3 | R1 318.0 | R2 325.7 | R3 331.4 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
VEEV SEC filings
27 Aug 2026
10-QSEC EDGAR
Quarterly report
26 Aug 2026
8-KSEC EDGAR
Results of operations
20 Aug 2026
8-KSEC EDGAR
Director or officer change
18 Jun 2026
8-KSEC EDGAR
Shareholder vote results
5 Jun 2026
10-QSEC EDGAR
Quarterly report
3 Jun 2026
8-KSEC EDGAR
Results of operations
4 May 2026
DEF 14ASEC EDGAR
Proxy statement
20 Apr 2026
8-KSEC EDGAR
Director or officer change
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.